Trust signals
Scope: Research and educational content only. Not medical advice.
Key takeaways
- The name GLOW does not provide the ingredient amounts needed for a calculation. Start with the individual amounts on the actual label.
- GHK and its copper complex are different chemical records; 340.38 is the molecular weight of copper-free GHK.
- The registered human wound study uses a topical gel. Its concentration is not an injectable schedule.
- Changing a dilution changes concentration while preserving the labeled ingredient amount.
How do you interpret a GLOW injection label?
A useful GLOW calculation requires an ingredient list, an amount for each ingredient and the final solution volume. These inputs answer what a measured volume contains. They do not tell you how often to administer it or what result it produces. A single GHK-Cu vial and a multi-ingredient blend require different calculations.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →On this page
- GHK versus GHK-Cu
- What the experiments tested
- Concentration and reverse checks
- Ingredient label worksheet
- Existing safety guidance
- Common questions
GHK and GHK-Cu: correct the chemical identity first
| Record | Formula in that record | Molecular weight | Interpretation |
|---|---|---|---|
| PubChem CID 73587 | C14H24N6O4 | 340.38 g/mol | Copper-free glycine-histidine-lysine |
| PubChem CID 71587328 | C14H23CuN6O4+ | 402.92 g/mol | The copper-containing structure represented by this specific record |
The 62.54 g/mol difference is calculated by subtracting the displayed record values. It reflects their different compositions. A product certificate may describe another salt, hydration state or analytical ion, so a mass-spectrometry peak needs its stated structure and charge. A matching name alone cannot resolve that identity.
What the GHK-Cu experiments actually tested
| Primary record | Model and exposure | Question answered |
|---|---|---|
| Maquart et al., 1993 | Rats with implanted wound chambers and local GHK-Cu injections | Extracellular matrix accumulation in an experimental wound model |
| NCT07437586 | Planned 60 participants; paired skin wounds; 0.1% w/w topical gel versus vehicle for 14 days | Time to complete wound epithelialization; recruiting with no posted results as checked October 3, 2026 |
The rat experiment concerns wound repair, not a measured cosmetic result in people. The registered topical study is a research plan, not a completed efficacy result. Neither record establishes an injection frequency for a GLOW blend. A gel concentration expressed as percent by weight is also different from an injectable solution expressed in mg/mL.
Reconstitution math: one ingredient, several final volumes
Use the final solution volume stated for the preparation. The denominator is final volume, which is not automatically identical to the amount of diluent added. These hypothetical examples hold the labeled ingredient amount at 10 mg and compare concentrations; they are not dosing schedules.
| Final volume | 10 mg divided by volume | Compared volume | Amount in that volume | Reverse check |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.1 mL | 1 mg | 1 / 10 = 0.1 mL |
| 2 mL | 5 mg/mL | 0.1 mL | 0.5 mg | 0.5 / 5 = 0.1 mL |
| 2.5 mL | 4 mg/mL | 0.1 mL | 0.4 mg | 0.4 / 4 = 0.1 mL |
| 4 mL | 2.5 mg/mL | 0.1 mL | 0.25 mg | 0.25 / 2.5 = 0.1 mL |
| 5 mL | 2 mg/mL | 0.1 mL | 0.2 mg | 0.2 / 2 = 0.1 mL |
For example, 10 mg in a final 2 mL gives 5 mg/mL. A 0.1 mL sample contains 0.5 mg; 0.5 divided by 5 returns 0.1 mL. If the final volume changes to 4 mL, that same sample contains 0.25 mg. The amount in the vial remains 10 mg in both examples.
A U-100 scale maps 100 marked units to 1 mL, so 10 marked units represent 0.1 mL. The scale is a volume reference. It does not mean 10 mg or establish biological potency. A 0.3 mL U-100 barrel has a capacity of 30 marked units.
A four-input label worksheet
| Input | Why the calculation needs it |
|---|---|
| Ingredient identity | GHK, GHK-Cu and a named blend are not interchangeable inputs |
| Amount per ingredient | A total blend amount cannot substitute for individual component amounts |
| Final volume | Concentration equals ingredient amount divided by this volume |
| Volume being compared | Amount in the sample equals concentration multiplied by this volume |
A certificate reporting identity or chromatographic area does not by itself provide all four inputs. In particular, an HPLC area percentage is not automatically a percentage by mass that can be multiplied by the vial label to revise its amount. That conversion requires a quantitative assay and its reporting basis.
Likewise, the primary records above do not establish a universal 30-day storage life, a plasma half-life for every GLOW blend or a mechanical shaking threshold. Those properties require formulation-specific measurements. An assumed value should not become a fact in a calculation.
Safety, side effects, and failure modes
Injection-site reactions: Redness, swelling and itching can occur at an injection site; the cited studies do not establish a GLOW-specific frequency or a standard 30-60-minute duration. Persistent nodules, warmth, or purulent discharge indicate infection and require medical evaluation.
Copper accumulation: An injected amount cannot be equated with dietary copper intake to establish tolerability. The primary records reviewed here do not supply long-term human data for a GLOW injection blend. Users with Wilson's disease (copper metabolism disorder) should not use copper-containing injectables.
Non-sterile technique: A preventable failure mode. Peptide injection with contaminated equipment causes abscess, cellulitis, and -- rarely -- systemic sepsis. There is no shortcut to aseptic technique.
Sourcing failure: A certificate of analysis reports the tests it contains, not every property of the supplied product. Identity, quantity and microbiological results are separate measurements.
Interaction with copper-chelating drugs: D-penicillamine and trientine (used in Wilson's disease) chelate copper and could theoretically compete with GHK. This is a pharmacological plausibility, not a documented clinical interaction. Inform a physician if taking copper-chelating medications.
Common questions
Is GLOW a single ingredient?
The name alone does not identify ingredient amounts. The calculation starts with the actual composition rather than treating the name as a chemical specification.
Does a 10 mg vial mean 10 mg of every ingredient?
No. A blend total may be the sum of several component amounts. Each needs its own concentration calculation.
Can the topical trial supply an injection dose?
Its 0.1% w/w gel and topical route do not specify a subcutaneous dose or cycle.
Where are the blend calculations?
See the GLOW component dosage and concentration guide for examples that track all ingredients at once.
Primary sources
- PubChem: GHK, CID 73587
- PubChem: copper-containing GHK structure, CID 71587328
- Maquart et al. 1993, PMID 8227353
- ClinicalTrials.gov, NCT07437586
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →